ARALEZ PHARMACEUTICALS INC. (NASDAQ:ARLZ) Files An 8-K Other Events
ME Staff 8-k
ARALEZ PHARMACEUTICALS INC. (NASDAQ:ARLZ) Files An 8-K Other EventsItem 8.01. Other Events
On May 3, 2017, the Board of Directors (the “Board”) of Aralez Pharmaceuticals Inc. (the “Company”) voluntarily agreed to a reduction of their cash retainers as part of the Company’s recently announced cost savings program. Specifically, the non-employee members of the Board have agreed to reduce their annual cash retainers by 50% for the next twelve (12) months. The significant reductions in annual cash retainers demonstrate the commitment of the Board and the Company to align the Board’s compensation program with the interests of Company shareholders.
About ARALEZ PHARMACEUTICALS INC. (NASDAQ:ARLZ) Aralez Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G. Its development products include YOSPRALA and Bilastine. Fibricor (fenofibric acid) is indicated as a complementary therapy along with diet for the treatment of hypertriglyceridemia, and as a complementary therapy along with diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG) and apolipoprotein B (Apo B). Fibricor is also used to increase high-density lipoprotein (HDL) cholesterol (HDL-C) in patients with hypercholesterolemia or mixed dyslipidemia. Cambia (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug (NSAID). ARALEZ PHARMACEUTICALS INC. (NASDAQ:ARLZ) Recent Trading Information ARALEZ PHARMACEUTICALS INC. (NASDAQ:ARLZ) closed its last trading session down -0.24 at 1.21 with 3,202,923 shares trading hands.